Loading…
Loading…
ABMD (Abiomed, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
GOTHENBURG, Sweden, May 28, 2026 /PRNewswire/ -- Getinge today announces that a jury in the United States District Court for the District of Massachusetts has delivered a verdict in favor of Abiomed Inc ("Abiomed") in a patent dispute between Getinge's subsidiary Maquet Cardiovascular LLC ("Maquet") and Abiomed. The jury found that Abiomed has not infringed any Maquet patents relating to intravascular heart pump technology.
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "IoMT Wearable Devices Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The IoMT wearable devices market was valued at USD 34.93 billion in 2023. It is expected to grow at a CAGR of 23.0% during the forecast period of 2024-2032 and attain a market value of USD 225.1 billion in 2032. The patent landscape is driven by advancements in sensor technology, AI integration, and connectivity solutions, enhancing diagnostic accuracy and personalised treatment. The global IoMT wearable devices patent landscape report offers an in-depth analysis of the dynamic patent environment. It explores innovations in sensor technologies, AI integration, and advanced connectivity solutions that are shaping the future of IoMT wearables. The report provides detailed segmentation by product type, modality, and application, highlighting key patents and emerging trends.
The U.S. health regulator on Thursday classified the recall of blood pumps by Abiomed, a Johnson & Johnson company, as the most serious and said their use could cause serious injuries or death.
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
DANVERS, Mass.--( BUSINESS WIRE )--Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in adult patients who receive Impella ECP support during an elective or urgent high-risk percutaneous coronary intervention (PCI).
There's a lot more ahead for these market giants.
NEW BRUNSWICK, N.J.--( BUSINESS WIRE )--Johnson & Johnson (NYSE: JNJ), the world's largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc. (“Offeror”), a wholly owned subsidiary of Johnson & Johnson, has extended the expiration date of its offer (the “Offer”) to acquire all of the outstanding shares of common stock of Abiomed, Inc. (NASDAQ: ABMD), for an upfront payment of $380.00 per share in cash, plus one non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved.
NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Elevate Credit, Inc. (NYSE: ELVT)'s sale to an affiliate of Park Cities Asset Management LLC for $1.87 per share. If you are an Elevate Credit shareholder, click here to learn more about your rights and options.
No recent filings indexed.